EGFR and cancer: These studies, together with our own findings, raise the possibility that HDAC inhibition could be employed to reactivate p66Shc-driven apoptotic pathways in NSC-like cancers or other cells that have silenced SHC1, thereby improving therapeutic responses to EGFR or MEK inhibition.